Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine

In line with current microbial risk reduction efforts, pathogen inactivation (PI) technologies for blood components promise to reduce the residual risk of known and emerging infectious agents. The implementation of PI of labile blood components is slowly but steadily increasing. This review discusse...

Descripción completa

Detalles Bibliográficos
Autor principal: Seltsam, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722787/
https://www.ncbi.nlm.nih.gov/pubmed/29255710
http://dx.doi.org/10.3389/fmed.2017.00219
_version_ 1783285072236904448
author Seltsam, Axel
author_facet Seltsam, Axel
author_sort Seltsam, Axel
collection PubMed
description In line with current microbial risk reduction efforts, pathogen inactivation (PI) technologies for blood components promise to reduce the residual risk of known and emerging infectious agents. The implementation of PI of labile blood components is slowly but steadily increasing. This review discusses the relevance of PI for the field of transfusion medicine and describes the available and emerging PI technologies that can be used to treat cellular blood products such as platelet and red blood cell units. In collaboration with the French medical device manufacturer Macopharma, the German Red Cross Blood Services developed a new UVC light-based PI method for platelet units, which is currently being investigated in clinical trials.
format Online
Article
Text
id pubmed-5722787
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-57227872017-12-18 Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine Seltsam, Axel Front Med (Lausanne) Medicine In line with current microbial risk reduction efforts, pathogen inactivation (PI) technologies for blood components promise to reduce the residual risk of known and emerging infectious agents. The implementation of PI of labile blood components is slowly but steadily increasing. This review discusses the relevance of PI for the field of transfusion medicine and describes the available and emerging PI technologies that can be used to treat cellular blood products such as platelet and red blood cell units. In collaboration with the French medical device manufacturer Macopharma, the German Red Cross Blood Services developed a new UVC light-based PI method for platelet units, which is currently being investigated in clinical trials. Frontiers Media S.A. 2017-12-04 /pmc/articles/PMC5722787/ /pubmed/29255710 http://dx.doi.org/10.3389/fmed.2017.00219 Text en Copyright © 2017 Seltsam. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Seltsam, Axel
Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine
title Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine
title_full Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine
title_fullStr Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine
title_full_unstemmed Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine
title_short Pathogen Inactivation of Cellular Blood Products—An Additional Safety Layer in Transfusion Medicine
title_sort pathogen inactivation of cellular blood products—an additional safety layer in transfusion medicine
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722787/
https://www.ncbi.nlm.nih.gov/pubmed/29255710
http://dx.doi.org/10.3389/fmed.2017.00219
work_keys_str_mv AT seltsamaxel pathogeninactivationofcellularbloodproductsanadditionalsafetylayerintransfusionmedicine

Ejemplares similares